Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 2;17(26):37448-37464.
doi: 10.1021/acsami.5c03469. Epub 2025 Jun 19.

iRGD-NaGd(MoO4)2: A Tumor-Targeted Magnetic Resonance Contrast Agent Activating Immunotherapy via the cGAS-STING Pathway

Ling Yu  1   2 , Fengkai Qiu  1   2   3   4 , Yumin Hu  1   2   3   4 , Tingting Liao  1   2 , Mengqian Zhai  1   2 , Ronghua Wu  1   2 , Qianhui He  1   2 , Huilin Hu  1   2 , Shuiwei Xia  1   2   3   4 , Junguo Hui  1   2   3   4 , Zufei Wang  1   2   3   4 , Yang Yang  1   2   3   4 , Rongfang Qiu  1   2   3   4 , Minjiang Chen  1   2   3   4 , Weiqian Chen  1   2   3   4 , Jianfei Tu  1   2   3   4 , Jiansong Ji  1   2   3   4 , Chenying Lu  1   2   3   4
Affiliations

iRGD-NaGd(MoO4)2: A Tumor-Targeted Magnetic Resonance Contrast Agent Activating Immunotherapy via the cGAS-STING Pathway

Ling Yu et al. ACS Appl Mater Interfaces. .

Abstract

Because of the high incidence and mortality of cancer, there is an urgent need for more effective tumor diagnostic imaging and treatment strategies. Single-molecule therapeutics have emerged as a promising strategy to address the limitations of independent imaging and therapeutic modalities, thereby significantly reducing adverse side effects for patients. For the first time, we successfully synthesized NaGd(MoO4)2 nanoparticles via a homogeneous precipitation method in polyol media, which serve as a single-molecule agent for MRI imaging and metallic immunotherapy. With the addition of iRGD, we obtained iRGD-NaGd(MoO4)2. The iRGD-NaGd(MoO4)2 nanoparticles exhibit excellent tumor-targeting capability and significantly enhance T1-weighted MRI contrast with a longitudinal relaxivity of 4.95 mM-1 s-1. In terms of antitumor immunotherapy, iRGD-NaGd(MoO4)2 not only directly activates the cGAS-STING pathway but also induces ferroptosis in tumor cells, resulting in the generation of aberrant dsDNA and thereby indirectly activating the STING pathway. The dual pathway elicits a tumor-specific immune response, plays a significant role in promoting the maturation of DC cells, activates DC and T cells to secrete high levels of TNF-α, IL-6 and other cytokines, and regulates the polarization of macrophages from M2 phenotype to M1 phenotype. This mechanism significantly suppresses tumor growth. Beyond the metallic immunotherapy induced by Mn2+, Zn2+, and Co2+, this study provides robust validation of MoO42- as an effective cGAS-STING agonist. Moreover, this study achieved the synergy of multiple disciplines including biomaterials, tumor immunotherapy and medical imaging. This not only promotes the innovative integration in various fields, but also provides new treatment strategies and imaging tools for cancer treatment, which has important clinical application prospects.

Keywords: MRI contrast agent; cGAS-STING pathway; immunotherapy; integration of diagnosis and treatment; tumor targeting.

PubMed Disclaimer